Maven Securities’s Amylyx Pharmaceuticals AMLX Stock Holding History

Maven Securities’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$695K	Buy	+50,000	New	+$703K	0.01%	351
2025 Q4	–	Sell	-70,000	Closed	-$951K	–	458
2025 Q3	$951K	Buy	+70,000	New	+$659K	0.02%	372
2024 Q3	–	Sell	-100,000	Closed	-$190K	–	866
2024 Q2	$190K	Buy	100,000 +75,000	+300%	+$145K	﹤0.01%	890
2024 Q1	$71K	Buy	+25,000	New	+$327K	﹤0.01%	332
2023 Q2	–	Sell	-100,000	Closed	-$2.93M	–	857
2023 Q1	$2.93M	Sell	100,000 -50,000	-33%	-$1.74M	0.06%	219
2022 Q4	$5.54M	Buy	+150,000	New	+$5.32M	0.13%	88

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Maven Securities's AMLX Position: Q1 2026 in Review

Maven Securities opened a new position in Amylyx Pharmaceuticals (AMLX) in Q1 2026: 50,000 shares worth $695K. The stake represents 0.01% of the portfolio and ranks #351 among its holdings. This is a return to the name: Maven Securities previously reported a position in AMLX as recently as Q3 2025.

Maven Securities first reported a position in AMLX in Q4 2022 and has held it in 6 quarters since. The position peaked at $5.54M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Maven Securities held 50,000 shares of Amylyx Pharmaceuticals worth $695K as of Q1 2026.
Amylyx Pharmaceuticals was a new Maven Securities position in Q1 2026.
Amylyx Pharmaceuticals made up 0.01% of Maven Securities's portfolio in Q1 2026, its #351 holding.
Maven Securities first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
Maven Securities's Amylyx Pharmaceuticals position peaked at $5.54M in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.